Business context and reporting period
This is Kitov Pharma Ltd.’s audited Form 20-F for the fiscal year ended December 31, 2017, prepared under IFRS as issued by the IASB. The request metadata names Purple Biotech, but the filing identifies the registrant as Kitov Pharma; the company adopted the Kitov Pharma name in January 2018. Kitov was a development-stage biopharmaceutical company with no product revenue. Its lead candidate, Consensi, was under FDA review; its subsidiary TyrNovo was developing preclinical oncology candidate NT219.
Financial performance and position
Amounts below are in U.S. dollars unless stated otherwise. The filing reports no revenue and no operating profitability; therefore, revenue growth and operating margins are not applicable.
| Metric | 2017 | 2016 | Change or context |
|---|---|---|---|
| Research and development expense | $4.640 million | $4.180 million | Up 9.5%, reflecting NT219 development and lower Consensi costs as that program neared completion. |
| General and administrative expense | $6.392 million | $3.003 million | Up 113%, including higher compensation and approximately $0.893 million of ISA investigation and class-action legal fees. |
| Other expense | $1.029 million | — | Primarily fair value of rights granted to TyrNovo minority shareholder Taoz. |
| Operating loss | $12.061 million | $7.183 million | Loss widened, mainly due to higher R&D, G&A and other expense. |
| Net loss | $13.008 million | $12.125 million | Included net derivative fair-value expense of $1.049 million in 2017 versus $5.019 million in 2016. |
| Loss per ordinary share | $0.07 | $0.11 | Basic and diluted. |
| Cash used in operating activities | $8.627 million | $6.262 million | Use increased with operating and legal costs. |
| Cash and cash equivalents | $3.947 million | $6.758 million | Short-term deposits were $3.488 million at year-end 2017, making cash plus deposits $7.435 million, versus $14.657 million in 2016. |
| Total assets / total liabilities | $14.183 million / $5.590 million | $14.914 million / $1.529 million | 2017 liabilities included derivative instruments of $3.042 million. |
| Total equity | $8.593 million | $13.385 million | Includes $1.280 million attributable to non-controlling interests in TyrNovo. |
At December 31, 2017, current assets were $7.983 million and current liabilities $4.068 million. The resulting working capital is $3.915 million, calculated from the audited balance sheet. The company reported no borrowings at year-end. It had accumulated losses of $38.567 million and stated that it had no material capital-expenditure commitments.
Material changes, outlook and risks
- Kitov acquired approximately 65% of TyrNovo in January 2017 for approximately $2.0 million cash and $1.8 million in shares. A further acquisition of about 27% was agreed in October, in exchange for 13,169,689 Kitov ordinary shares; closing was pending tax clearance and expected by March 15, 2018.
- Consensi’s NDA was filed by the FDA for full review, with a PDUFA target date of May 31, 2018. FDA information requests included additional chemistry data; the company said the additional renal-function study report could potentially extend the review by up to 90 days. Management expected approval later in 2018, but approval was not assured.
- The Phase III/IV renal-function trial met its primary endpoint (p=0.019); the company reported a statistically significant reduction in serum creatinine from baseline (p=0.0005). These were company-reported clinical results, not FDA approval or proof of commercial benefit.
- Management expected to submit an IND for NT219 in the first half of 2019 after preclinical and toxicology work. NT219 remained preclinical; clinical efficacy and safety had not been established.
- The company reported no revenue and expected continuing losses. Management said existing resources were expected to meet liquidity needs for at least 12 months and fund planned near-term development, while also stating additional funding could be required. Operating cash use was $8.627 million in 2017.
- Key uncertainties included FDA review and possible added studies, the ongoing Israeli Securities Authority investigation into disclosures concerning the Consensi Phase III trial, and related class-action proceedings in Israel and the United States. The company recorded no litigation provision, citing uncertainty; it incurred about $0.893 million in related legal fees in 2017.
- TyrNovo had approximately NIS 5.5 million (about $1.6 million) in potential IIA grant royalty obligations, plus interest, and restrictions on transferring funded know-how or manufacturing outside Israel. The filing also describes possible dilution from equity compensation, warrants and the TyrNovo share exchange.
- Management said the prior-year internal-control material weakness had been remediated in 2017 and concluded controls were effective at year-end. The auditor issued an unqualified opinion on the financial statements; it did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the registrant and period: this filing is Kitov Pharma’s FY2017 annual report, notwithstanding the Purple Biotech metadata and “2017 Q4” label.
- Track the FDA’s Consensi decision, any review-date extension, and the status and regulatory significance of the renal-function report.
- Check the outcome and financial consequences of the ISA investigation and related lawsuits, including insurance coverage and any indemnification or settlement costs.
- Verify the closing and final share issuance for the TyrNovo minority-share exchange, and resulting ownership, dilution and related-party rights.
- Reassess cash runway against reported cash use, development spending, financing needs and the company’s stated 12-month liquidity expectation.
- Monitor NT219’s preclinical and IND milestones, IIA obligations, and whether further equity, warrant exercise or other financing changes the share count.